Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Air Products and Chemicals

Broadcom

Bank of Nova Scotia

Cardinal Health

CME Group

Illinois Tool Works

Main Street Capital

McCormick

Altria

Nucor

Realty Income Corp

Philip Morris

SPDR S&P 500 ETF Trust

Stryker

W. P. Carey

Xcel Energy

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: December 21-January 3, 2021

DUBLIN , Dec. 16, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, made two announcements today regarding its executive committee. Ivan Fong has been named as general counsel and secretary, succeeding Brad Lerman, who will retire at the end of January.

Medtronic announces two executive committee changes

SHENZHEN, China, Dec. 16, 2021 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 01302.HK) announced that it has extended its agreements with Medtronic to further the strategic collaboration on the "HeartTone™ domestic pacemaker project" and to start the collaboration on domestically-made MRI-conditional pacemakers. Together with MRI-conditional leads, these products will address growing MRI-related therapeutic needs in China.

LifeTech and Medtronic Further Strategic Collaboration to Open New Chapter of Domestically-Made MRI-Conditional Pacemakers

The company revealed it had received a warning letter from the FDA about one of its California facilities.

Why Medtronic Sank by 6% Today

MARLTON, N.J., Dec. 15, 2021 /PRNewswire/ -- Virtua Health and Medtronic plc (NYSE:MDT) announce a five-year partnership focused on improving delivery of quality care for residents of South Jersey, particularly those who reside in underserved communities or face systemic barriers to care.

Virtua Health and Medtronic Share Plans to Reimagine Traditional Health Care Models

Medtronic Plc (NYSE: MDT) received a warning letter from the FDA highlighting certain concerns related to medical device quality requirements at the Company's diabetes business headquarters. The Company said that the letter focused on inadequacies in risk assessment, complaint handling, and device recalls at Medtronic's facility in Northridge, California.

Medtronic Shares Fall After FDA Warning Letter To Its Diabetes Business

Shares of Medtronic MDT, -1.04% gained 0.3% in premarket trading on Wednesday after the company said it received a warning letter from the Food and Drug Administration following an inspection at a factory that makes its MiniMed 600 series insulin infusion pump and a remote-controller device for MiniMe 508 and Paradigm pumps. The company said it will make corrections to quality system requirements.

Medtronic warned by FDA about manufacturing facility for insulin pumps

DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) on December 9 for the company's Northridge, California, facility, the headquarters for its Diabetes Business. The warning letter was issued following an inspection that concluded in July 2021 related to recalls of the MiniMed™ 600 series insulin infusion pump, and a remote controller device for MiniMed™ 508 and Paradigm™ pumps.

Medtronic Diabetes receives FDA warning letter

T. Rowe Price Group

Upcoming Ex-Dividend Dates: December 15-27, 2021

FDA clearance expands use of the INVOS™ 7100 system, helping clinicians better monitor organ-specific oxygen levels and identify warnings signs for neonates and children earlier DUBLIN, Dec. 14, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its INVOS™ 7100 cerebral/somatic oximetry system for children from birth through age 18. The INVOS system picks up key signals to inform time-critical decisions by pediatric clinicians related to hemodynamic management, ventilation, and resuscitation for premature infants, neonates, children, and other patients treated by pediatric clinicians.

Medtronic INVOS™ 7100 Cerebral/Somatic Oximetry System receives 510(k) clearance for pediatric indications

DUBLIN, Dec. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases elimination of oral opioids, and decrease in payer costs following balloon kyphoplasty (BKP) or vertebroplasty (VP) procedures in patients suffering from spinal fractures, known as vertebral compression fractures (VCF).1 This study, sponsored by Medtronic, is the first published study to evaluate the effect of BKP and VP on opioid reduction as a primary outcome. An estimated 800,000 VCFs occur in the United States every year.2 They are associated with debilitating pain, spinal deformity, increased mortality, and increased healthcare-resource utilization in elderly patients.3-5 VCFs are often treated with conservative medical management (CMM), including bed rest, back bracing, and prescription oral opioids.

New study finds procedures treating spinal fractures associated with reduction in opioid use and decreased payer costs

Abbott Labs

Johnson & Johnson

When selecting dividend stocks to buy, investors are faced with a variety of choices. However, we like healthcare stocks for many reasons, particularly given inherent recession resilience and long-term earnings growth.

3 Healthcare Stocks for Long-Term Dividend Growth

DUBLIN, Dec. 10, 2021 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 9, 2021, approved the fiscal year 2022 third quarter cash dividend of $0.63 per ordinary share, representing a 9 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2021.

Medtronic announces cash dividend for third quarter of fiscal year 2022

Apple

AbbVie

Blackrock Inc

Amplify CWP Dividend & Option Income ETF

Domino's Pizza

Cohen & Steers Closed-End Opportunity Fund

Home Depot

JPMorgan Chase & Co

Mastercard

Global X MLP ETF

Microsoft

NIKE

Pacer Metaurus US Large Cap Target Dividend 400 ETF

Invesco NASDAQ Next Gen 100 ETF

Invesco Nasdaq 100 ETF

iShares Mortgage Real Estate ETF

Starbucks

Schwab US Dividend Equity ETF

Schwab Strategic Trust-Schwab International Dividend Equity ETF

Global X MSCI SuperDividend Emerging Markets ETF

Global X Superdividend ETF

The portfolio generated $1,067 in dividends during the month, an improvement over August. YTD, I've received $12,700. I closed out my positions in REM, DIS, MLPA, and SPYD.

My Dividend Growth Portfolio November Update: 27 Holdings, 7 Buys, 4 Sells

Medical device companies are struggling with difficult economic conditions and a COVID-19 resurgence.

Here's Why Medtronic Stock Dipped 11% in November

The receipt of the Health Canada license for Medtronic's (MDT) Hugo RAS System is likely to enhance accessibility to robotic-assisted surgery in Canada.

Medtronic (MDT) Gets Health Canada License for Hugo RAS System

Medtronic plc (NYSE: MDT) has received a Health Canada license to use the Hugo robotic-assisted surgery system. According to a news release, those procedures make up about half of all robotic surgery procedures performed today.

Canada Approves Medtronic's Hugo Robotic-Assisted Surgery Platform

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.

Medtronic (MDT) Gets Health Canada License for GI Genius Module

Cloud DX (TSX-V:CDX, OTCQB:CDXFF) said that it has been selected by Medtronic Canada ULC—a subsidiary of Medtronic PLC (NYSE:MDT)—for providing virtual healthcare to patients across Canada. The Brampton, Ontario-based company said that the partnership advances Medtronic's commitment to improving patient outcomes and lowering overall costs along the care continuum.

Cloud DX partners with Medtronic Canada ULC to provide virtual healthcare to patients across Canada

Medtronic selected Cloud DX for virtual and remote patient monitoring (RPM) solutions in exclusive corporate agreement WATERLOO, ON / ACCESSWIRE / December 1, 2021 / Cloud DX (TSXV:CDX) (OTCQB:CDXFF) has been selected by Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE:MDT), a global leader in healthcare technology, to provide world-class virtual healthcare to patients across Canada. This partnership advances Medtronic's commitment to improving patient outcomes and lowering overall costs along the care continuum.

Cloud DX Selected by Medtronic for National Collaboration

Walgreens

Just when you thought it was starting to look safer, yet another COVID-19 variant comes around.

5 Health Care Dividend Aristocrats to Buy for 2022 as Yields Plunge Once Again

Aflac

Amcor Plc

Atmos Energy

Becton, Dickinson and Co.

Caterpillar

Chubb

Clorox

Ecolab

General Dynamics

Even after the dip on Black Friday NOBL is still having a positive return in November. I present 3 strategies that theoretically can beat the dividend aristocrat index in the long term.

Best Dividend Aristocrats For December 2021

News for Medtronic Stock (MDT)